Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction

European Journal of Pharmacology

Volumn 742, Issue , 2014, Pages 47-54

  Kubica, Aldona ^a   Kasprzak, Michał ^a   Siller Matula, Jolanta ^b   Koziński, Marek ^a   Pio Navarese, Eliano ^a   Obońska, Karolina ^a   Andruszkiewicz, Anna ^a   Sztuba, Beata ^c   Fabiszak, Tomasz ^a   ͆wiątkiewicz, Iwona ^a   Paciorek, Przemysław ^a   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c National Health Fund   (Poland)

Author keywords

ADP induced platelet aggregation; Clopidogrel; Effectiveness of antiplatelet therapy; Myocardial infarction

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

AGED; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; TIME;

ADENOSINE DIPHOSPHATE; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS;

EID: 84907646258     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.08.009     Document Type: Article

References (40)

1. K. Aksu, A. Donmez, and G. Keser Inflammation-induced thrombosis: mechanisms, disease associations and management Curr. Pharm. Des. 18 2012 1478 1493
2. I. Bernlochner, S. Steinhubl, S. Braun, T. Morath, J. Jaitner, J. Stegherr, J. Mehilli, N. von Beckerath, A. Schömig, A. Kastrati, and D. Sibbing Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment Thromb. Haemost. 104 2010 1193 1200
3. E. Cecchi, R. Marcucci, R. Paniccia, B. Bandinelli, S. Valente, C Giglioli, C. Lazzeri, G.F. Gensini, R Abbate, and L. Mannini Effect of blood hematocrit and erythrocyte deformability on adenosine 5′-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy Am. J. Cardiol. 104 2009 764 768
4. H. Chu, W.L. Chen, C.C. Huang, H.Y. Chang, H.Y. Kuo, C.M. Gau, Y.C. Chang, and Y.S. Shen Diagnostic performance of mean platelet volume for patients with acute coronary syndrome visiting an emergency department with acute chest pain: the Chinese scenario Emerg. Med. J. 28 2011 569 574
5. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Camoin, L. Bali, M. Lambert, I. Juhan-Vague, M.C. Alessi, and J.L. Bonnet Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response Thromb. Res. 123 2009 597 603
6. T. Cuisset, J. Quilici, C. Grosdidier, L. Fourcade, B. Gaborit, M. Pankert, L. Molines, P.E. Morange, J.L. Bonnet, and M.C. Alessi Comparison of platelet reactivity and clopidogrel response in patients ≤75 years versus >75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome Am. J. Cardiol. 108 2011 1411 1416
7. 12 expressing leukocytes Basic Res. Cardiol. 105 2010 379 387
8. G. Endler, A. Klimesch, H. Sunder-Plassmann, M. Schillinger, M. Exner, C. Mannhalter, N. Jordanova, G. Christ, R. Thalhammer, K. Huber, and R. Sunder-Plassmann Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease Br. J. Haematol. 117 2002 399 404
9. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, N. Saut, D. Faille, M. Lambert, I. Juhan-Vague, J.L. Bonnet, and M.C. Alessi Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am. J. Cardiol. 101 2008 1088 1093
10. K.L. Funck-Jensen, J. Dalsgaard, E.L. Grove, A.M. Hvas, and S.D. Kristensen Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction Platelets 24 2013 528 537
11. H. Ge, Y. Zhou, X. Liu, X. Nie, Z. Wang, Y. Guo, W. Chen, and Q. Yang Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty Angiology 63 2012 62 66
12. (12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention Atherosclerosis 217 2011 465 472
13. C.M. Gibson, H.Q. Ly, S.A. Murphy, L.N. Ciaglo, M.C. Southard, E.B. Stein, J.L. Buros, M.S. Sabatine, C.P. Cannon TIMI Study Group Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28) Am. J. Cardiol. 98 2006 761 763
14. H.M. Hall, S. Banerjee, and D.K. McGuire Variability of clopidogrel response in patients with type 2 diabetes mellitus Diabetes Vasc. Dis. Res. 8 2011 245 253
15. W.B. Hillegass, B.C. Brott, J.C. Dobbs, S.E. Papapietro, V.K. Misra, and G.J. Zoghbi Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview Vasc. Health Risk Manag. 7 2011 445 459
16. K. Hoshino, H. Horiuchi, T. Tada, J. Tazaki, E. Nishi, M. Kawato, T. Ikeda, H. Yamamoto, M. Akao, Y. Furukawa, S. Shizuta, M. Toma, T. Tamura, N. Saito, T. Doi, N. Ozasa, T. Jinnai, K. Takahashi, H. Watanabe, Y. Yoshikawa, N. Nishimoto, C. Ouchi, T. Morimoto, T. Kita, and T. Kimura Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention Circ. J. 73 2009 336 342
17. S.M. Jafri, T. Ozawa, E. Mammen, T.B. Levine, C. Johnson, and S. Goldstein Platelet function, thrombin and fibrinolytic activity in patients with heart failure Eur. Heart J. 14 1993 205 212
18. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, S.J. Hwang, C.H. Kwak, and J.Y. Hwang Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc. Interv. 3 2010 731 741
19. M. Karaźniewicz-Łada, D. Danielak, and F. Główka Genetic and non-genetic factors affecting the response to clopidogrel therapy Expert Opin. Pharmacother. 13 2012 663 683
20. V. Khode, J. Sindhur, D. Kanbur, K. Ruikar, and S. Nallulwar Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: a case control study J. Cardiovasc. Dis. Res. 3 2012 272 275
21. N. Kiliçli-Camur, R. Demirtunç, C. Konuralp, A. Eskiser, and Y. Başaran Could mean platelet volume be a predictive marker for acute myocardial infarction? Med. Sci. Monit. 11 2005 387 392
22. M. Koziński, L. Bielis, J. Wisniewska-Szmyt, J. Boinska, W. Stolarek, A. Marciniak, A. Kubica, Z. Grabczewska, E.P. Navarese, F. Andreotti, J.M. Siller-Matula, D. Ros̈ć, and J. Kubica Diurnal variation in platelet inhibition by clopidogrel Platelets 22 2011 579 587
23. A. Kubica, M. Kozinski, G. Grzesk, T. Fabiszak, E.P. Navarese, and A. Goch Genetic determinants of platelet response to clopidogrel J. Thromb. Thrombolysis 32 2011 459 466
24. A. Kubica, M. Koziński, G. Grzes̈k, and A. Goch Clinical significance of interactions between clopidogrel and proton pump inhibitors Kardiol. Pol. 69 2011 610 616
25. L.A. Malek, M. Grabowski, M. Spiewak, K.J. Filipiak, M. Szpotanska, T. Imiela, Z. Huczek, D. Bobilewicz, and G. Opolski Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects J. Thromb. Thrombolysis 24 2007 301 305
26. J. Mehta, and P Mehta Platelet function studies in heart disease VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside Circulation 60 1979 497 503
27. S.R. Mehta, J.P. Bassand, S. Chrolavicius, R. Diaz, J.W. Eikelboom, K.A. Fox, C.B. Granger, S. Jolly, C.D. Joyner, H.J. Rupprecht, P. Widimsky, R. Afzal, J. Pogue, and S. Yusuf Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N. Engl. J. Med. 363 2010 930 942
28. 12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight Thromb. Haemost. 108 2012 338 348
29. E.P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, F. Castriota, S. De Servi, J. Kubica, and G. De Luca Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials QJM 104 2011 561 569
30. P. Osmancik, P. Paulu, P. Tousek, V. Kocka, and P Widimsky High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel J. Thromb. Thrombolysis 33 2012 349 354
31. V.L. Serebruany, A.I. Malinin, W. Ziai, A.N. Pokov, D.L. Bhatt, M.J. Alberts, and D.F. Hanley Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial Stroke 36 2005 2289 2292
32. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schömig, A. Kastrati, and N. von Beckerath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J. Am. Coll. Cardiol. 53 2009 849 856
33. ∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
34. J.M. Siller-Matula, G. Delle-Karth, I.M. Lang, T. Neunteufl, M. Kozinski, J. Kubica, G. Maurer, K. Linkowska, T. Grzybowski, K. Huber, and B. Jilma Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study J. Thromb. Haemost. 10 2012 529 542
35. F.B. da Silva, G.L.G. de Almeida Junior, A. Neno, J. Kezen, M. Spelta, A. Godomiczer, R. Villela, B. Hellmuth, S.S. Xavier, and R.H. da Costa Lins Resistance to clopidogrel: prevalence and associate variables Arq. Bras. Cardiol. 99 2012 1135 1141
36. U.S. Tantry, Y.H. Jeong, E.P. Navarese, J. Kubica, and P.A. Gurbel Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev. Cardiovasc. Ther. 11 2013 447 462
37. Y. Wu, H. Wu, C. Mueller, C.M. Gibson, S. Murphy, Y. Shi, G. Xu, and J. Yang Base-line platelet count and clinical outcome in acute coronary syndrome Circ. J. 76 2012 704 711
38. K. Yamamoto, U. Ikeda, K. Furuhashi, M. Irokawa, T. Nakayama, and K. Shimada The coagulation system is activated in idiopathic cardiomyopathy J. Am. Coll. Cardiol. 25 1995 1634 1640
39. S. Yokoyama, H. Ikeda, N. Haramaki, H. Yasukawa, T. Murohara, and T. Imaizumi Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates J. Am. Coll. Cardiol. 45 2005 1280 1286
40. J. Yu, R. Mehran, G.D. Dangas, B.E. Claessen, U. Baber, K. Xu, H. Parise, M. Fahy, A.J. Lansky, B. Witzenbichler, C.L. Grines, G. Guagliumi, R. Kornowski, J. Wohrle, D. Dudek, G. Weisz, and G.W. Stone Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial JACC Cardiovasc. Interv. 5 2012 1231 1238